Australia markets closed
  • ALL ORDS

    7,529.00
    -14.60 (-0.19%)
     
  • AUD/USD

    0.7019
    +0.0015 (+0.21%)
     
  • ASX 200

    7,245.10
    +3.90 (+0.05%)
     
  • OIL

    67.87
    +1.61 (+2.43%)
     
  • GOLD

    1,783.60
    -0.30 (-0.02%)
     
  • BTC-AUD

    69,510.16
    -1,349.05 (-1.90%)
     
  • CMC Crypto 200

    1,253.87
    -187.89 (-13.03%)
     

Soleno Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

REDWOOD CITY, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 2:40 PM Eastern Time.

A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting